Parliament Workbench
Data: Official Report to 18 Nov 2026

Official Report · Committee

Section 23 Reports

“Prescribing in general practice in Scotland”

Wednesday 30 January 2013 Public Audit Committee About 09:30 Committee business 75 contributions · 11 speakers

Speakers

Choose an MSP to read only their contributions

The record

75 contributions
Iain Gray Lab The Convener · East Lothian
link

From our first panel we will hear evidence on a just-laid section 23 report by the Auditor General for Scotland, entitled “Prescribing in general practice in Scotland”. The Auditor General is with us to speak to the report and answer questions. She has with her Barbara Hurst, who is director of Audit Scotland’s performance audit group, and Tricia Meldrum, who is also from the performance audit group.I ask the Auditor General to introduce the report.

Caroline Gardner Auditor General for Scotland
link

Thank you, convener.The national health service in Scotland spends around £1 billion a year on prescribing in general practice, which is around 10 per cent of NHS boards’ budgets. Last year, general practitioners issued 91 million prescriptions. In the report, which follows up reports that we published in 1999 and 2003, we have tried to assess how well the NHS is managing that spending.Overall, we found that the NHS has done a good job in improving its management of GP prescribing. Spending fell by 11 per cent in real terms over the seven years from 2004 at the same time as the volume of prescriptions rose by a third. That is in contrast with what happened previously—in the seven years up to 2004, spending increased by 50 per cent in real terms. There has therefore been a genuine shift in the direction of travel for spend at a time when the volume of prescriptions is increasing.One of the main reasons for that is the support and guidance that are now being provided to GPs to help them to manage their prescribing. That is provided in order both to keep the costs down and to meet the needs of patients who require drug treatment. The support includes support for GPs from prescribing advisers who are employed by health boards, agreed local joint formularies that give guidance to GPs in primary care and prescribers in hospitals on the sorts of drugs to prescribe, and published best-practice clinical guidelines to help GPs to ensure that they hit the clinical needs of their patients.Overall, the NHS now has much better information on GP prescribing, and NHS boards and GPs are using that information to target the areas where they can improve. We are seeing that in the costs of prescribing as well as in the quality that is achieved.In an area that accounts for more than £1 billion of spending, the NHS needs to continue to look for opportunities for improvements and savings. We have identified scope for further potential savings of around £26 million a year without patient care being affected. That could be achieved by two main measures: reducing unnecessary waste, for example as a result of patients getting repeat prescriptions for drugs that they no longer take; and reducing the use of drugs that are considered to be less suitable for prescribing, for example because better or more cost-effective drugs are available.We looked at the impact of the abolition of prescription charges from 2011 to see whether that has had an impact on prescribing. Overall, we think that it is too early to tell whether there has been an impact, but we have certainly not so far found any evidence of a significant change. We will continue to keep the matter under review. We have also recommended that the Scottish Government monitor the impact annually.In looking ahead at this important area of NHS spending, we know that demographic factors including the age of patients and deprivation are associated with higher levels of GP prescribing. Lifestyle factors, such as obesity, smoking and alcohol misuse, and associated illnesses, also have effects. That means that levels of prescribing are likely to continue to increase in the future, but some of the effects on spending will be offset by other factors, particularly falls in the prices of some drugs as they come off patent. We have estimated that in 2012-13 there will be savings of around £86 million in general practice from drugs that come off patent.Finally, we looked at the quality and safety of prescribing from the patient’s point of view, in particular in respect of the challenges facing patients who take a number of different drugs. Those people have a higher risk of either side-effects or interactions between the drugs that they take. We found that more than 900,000 people in Scotland are taking four or more different drugs at any one time. In October 2012, the Scottish Government issued guidance on reviewing and improving prescribing for patients taking multiple drugs. We have recommended that NHS boards work with GPs to implement those guidelines and ensure that those patients are being treated as safely as possible.I will stop there. We are happy to answer the committee’s questions.

Iain Gray Lab The Convener · East Lothian
link

Thank you very much. As we are the Public Audit Committee, I feel that I should start by acknowledging what a good news story the report appears to be. The report states:“The quantity of drugs prescribed increased by 33 per cent between 2004/05 and 2011/12. Spending on drugs fell by 11 per cent in real terms over the same period”.That is surely the kind of information that should gladden the heart of any Public Audit Committee member. It is a remarkable story.I just want to tease out why that has happened. The report states that one reason for it has been an increase in prescribing of drugs that have come off patent; the report points to a drop of as much as 94 per cent in cost when a proprietary drug is replaced by a generic equivalent. I presume that drugs come off patent all the time, while new drugs are developed and come on to the market. Is the change that we are seeing in this respect because, for some reason, a lot of drugs came off patent and became cheaper, or are we seeing a real change in prescribing behaviour within the NHS?

Caroline Gardner Auditor General for Scotland
link

I think that it is the latter: we are seeing a real improvement in prescribing behaviour. You are right that it makes a difference when treatments become available as generic drugs rather than patented drugs, but that has always been the case. When we looked at GP prescribing back in 1999 and 2003, we found a much higher proportion of drugs being prescribed as branded drugs than as generics. The thing that has made a real difference is that NHS boards have been working with general practices to support them in targeting where they can improve their prescribing and to really change that behaviour. Tricia Meldrum can give a couple more examples of where that may have been the case.

Tricia Meldrum Audit Scotland
link

We found that NHS boards now employ teams of staff who work with GP practices to target areas for improvement. For example, there are now good-quality data available on GP prescribing, so data analysts can analyse those data to find out what are the areas that can be targeted for improvement within a particular board, practice or community health partnership.Boards also provide prescribing advisers, who may be pharmacists who have specialist knowledge of drugs and of best clinical practice and clinical guidelines. Again, they can work with GP practices to raise awareness of best practice. We also found examples of boards employing pharmacists to work with GP practices, where they would be based for some sessions each week to work either with the GPs or with patients directly on things such as medication reviews. That has really helped the GP practices to target where they can improve their prescribing. Such things are making a big difference.There are also now joint local formularies, which set out the agreed drugs that are recommended for use locally. Those are now agreed between general practices and hospitals. That provides continuity of care and is also making a difference.

Mary Scanlon Con Highlands and Islands
link

This is not my prepared question, but your reference to data analysts brought me back to exhibit 5 in the report. A rough glance at that graph suggests that there is about £30 more spending per head on GP prescribing in NHS Fife than in the Greater Glasgow and Clyde NHS Board area. Given all those best-practice initiatives, clinical guidelines, data analysis and advice initiatives on prescribing, why do we see such a variation there?

Tricia Meldrum Audit Scotland
link

We have made recommendations about certain areas that boards can continue to target in that respect and have recommended that boards with fewer prescribing support staff and higher prescribing quantities or costs might want to consider whether there is scope for a spend-to-save initiative to improve or increase the prescribing support that is available to general practices.

Mary Scanlon Con Highlands and Islands
link

There seems to be quite a variation.I want to ask about pages 16, 17 and 20. I have to say that I was surprised by the recommendation on page 20 that“The Scottish Government should ... remove the incentive for pharmacists to over-order repeat drugs as part of the changes to the community pharmacy contract”.It seems incredible that there is almost an in-built incentive to over-order drugs, given that we have been asking patients not to stockpile or waste medication.Perhaps I can tie that in with information that is presented in paragraphs 39 to 42. I note, for example, that it was found that £110 million-worth of drugs were being kept in people’s homes. What can the community pharmacy contract do about that?My third question relates to a point that the Auditor General made. Anyone reading it would find it odd, but I see from the report that NHS Lanarkshire prescribes five times more“drugs classed as less suitable for prescribing”than NHS Lothian. Setting out a definition of that “less suitable”, the report says:“This does not mean they should not be prescribed at all but that the evidence of their benefit is uncertain, more effective drugs have superseded them, or they have significant side effects.”I know that this is not the Health and Sport Committee but, from a financial point of view, I am quite amazed to see such a disparity and that such a concern still exists after all these years.

Caroline Gardner Auditor General for Scotland
link

I will answer your first question on the community pharmacy contract. Tricia Meldrum and Barbara Hurst will pick up from there.We have seen how much scope there can be in the GP contract to improve the effectiveness of primary care and to align it with the rest of what the health service and public services more generally are doing, and this seems to be a real opportunity to move the community pharmacy contract in the same direction. There are great initiatives, including the minor ailments initiative, which allows patients to register with a community pharmacy for management of their condition. We think that there is scope to take that further by shifting the incentives from a payment-per-item-prescribed system to a more effective and cost-effective prescribing system. The high-level recommendation is very much about negotiating the contract to improve prescribing as part of the wider management of patients’ health.Tricia Meldrum will tell the committee about specific things that could be improved.

Mary Scanlon Con Highlands and Islands
link

I am sorry—I should just say that on re-reading that paragraph I find that the £110 million figure applies to England. The figure might not be as much in Scotland. Do you have a comparable figure for Scotland?

Tricia Meldrum Audit Scotland
link

One of the risks that have been identified with the repeat prescribing service is the potential for patients to get some of their drugs more frequently than they need them. For example, patients could be prescribed painkillers to take “as required”—in other words, when their pain is bad—and would therefore not be taking the drugs all the time. However, they might end up with a repeat prescription before they reached the end of their supply. We wanted to flag up those kinds of risks.

Mary Scanlon Con Highlands and Islands
link

Is the community pharmacy contract about to be renegotiated, changed or reviewed to address that issue?

Tricia Meldrum Audit Scotland
link

Discussions are on-going. We know that significant changes have been made in the community pharmacy contract with regard to, for example, the minor ailments and chronic medication services, but we wanted to flag up certain issues about repeat prescribing.Boards raised with us issues around public awareness campaigns that tell people to stock up on medicines before Christmas, for example, when practices are closed. Again, as with the repeat prescription service, we recognise the value to patients of their doing that, but people who were stocking up for Christmas were not necessarily cutting back on repeat prescriptions after that time, which meant that stockpiles developed.09:45

Mary Scanlon Con Highlands and Islands
link

It is not just individuals who are stocking up; there seems to be poor practice in care homes as well.Could you respond to the second part of my question, about drugs that are classed as “less suitable” or for which “evidence ... is uncertain” on their benefits and so on?

Tricia Meldrum Audit Scotland
link

As new evidence comes on stream, new drugs are developed, new trials take place and new research takes place, there is a need to ensure that the formulary is keeping pace. For example, there is no clear evidence that co-codamol has any additional benefit over paracetamol for certain patients, so paracetamol might be the more cost-effective treatment. The same applies to certain migraine drugs, such as Migraleve. We are not saying that those drugs have no value, but it might be that they have been superseded by alternative drugs. We need to ensure that the formulary picks up on the most effective drugs and that the prescribing support team works with GPs to ensure that there is compliance with the local formulary.Lanarkshire has quite low levels of prescribing support compared with some boards; there is disparity.

Mary Scanlon Con Highlands and Islands
link

You are saying that the low level of prescribing support and advice in Lanarkshire would explain why the prescription rate of unsuitable drugs by that health board is five times greater than, say, the rates in NHS Lothian and NHS Borders.

Tricia Meldrum Audit Scotland
link

I cannot say that that is the only reason, but I think that that would be one of the issues. NHS Lanarkshire might want to consider whether there might locally be scope for spend-to-save initiatives.

Colin Beattie SNP Midlothian North and Musselburgh
link

I echo the convener’s comment that this is a good report; it is probably one of the better ones that have come before us. However, as the convener said, we are the Public Audit Committee, so we have to look for something to pick on.Paragraph 20 notes that spending on drugs is lower in the United Kingdom than it is in the rest of Europe. I am quite intrigued by that. It makes a comparison between the UK and states that have insurance-based healthcare systems. Does that imply that state and private health insurance systems tend to be more expensive, because they do not focus as much on generic drugs but focus instead on branded drugs?

Caroline Gardner Auditor General for Scotland
link

There is more prescribing of generic drugs in the UK than there is in the places in Europe with which we compared the UK. We have not fully investigated the reasons for that, but we think that the key is that we can use the purchasing power of the NHS through the price-regulation scheme. That is not to say that countries in which there are insurance-based schemes could not have such a national negotiation, although they tend not to. Their negotiations tend to involve the insurance provider at regional level.

Colin Beattie SNP Midlothian North and Musselburgh
link

I assume that, in the UK and Scottish contexts, there is no indication that the private system that we have, which operates alongside the NHS, is more expensive in terms of the drugs that it prescribes.

Caroline Gardner Auditor General for Scotland
link

We did not consider that in this audit. Tricia Meldrum and Barbara Hurst are indicating to me that we are not aware of any relevant information on that matter. We have simply considered the way in which the NHS prescribes drugs and, in particular, trends in that over time.

Colin Beattie SNP Midlothian North and Musselburgh
link

It would have been interesting to see such a comparison.The one thing that is missing from paragraph 20 is the volume of drugs that is involved in the various countries. That would have been interesting to know. Do you have that?

Caroline Gardner Auditor General for Scotland
link

I do not think that that information is available. We can do it within Scotland and the UK, because we have the figures for the daily dosage units. For countries outside the UK, we just converge overall spending.

Colin Beattie SNP Midlothian North and Musselburgh
link

The same question applies to prescribing in deprived areas. In the past, the committee has focused on the more deprived areas of Scotland. Paragraph 72 states:“Practices serving the most deprived populations prescribe on average 46 per cent more drugs per head of population than those in the least deprived areas ... Spending is also 37 per cent higher per head of population.”That creates a huge skew in the way in which prescriptions work because, to produce the sort of average that you bring out, the least deprived areas must be much cheaper to compensate. Given that there are relatively few practices in deprived areas, are the doctors in those areas prescribing far more than doctors in other areas? Is any more information available on that?

Caroline Gardner Auditor General for Scotland
link

There is some more information on that. If you look further on in the report, you will see some of the points that we have drawn out. First, we know that patients who receive many drugs together tend to be older patients or people who live in more deprived areas. Secondly, when we look at the association between deprivation and the prescribing of particular types of drug, we find that there is not a consistent relationship.Tricia Meldrum will tell you a bit more about the relationship between deprivation and prescribing at practice level and more generally.

Tricia Meldrum Audit Scotland
link

Very high-quality data are now available on prescribing and patient characteristics that have allowed us to do such analysis for the first time. We found that the strongest relationship was with the use of painkillers, and use of hypnotics and anxiolytics—sleeping drugs and drugs to control anxiety. We found that there was still a significant relationship with statins—in other words, there is greater prescribing of statins in more deprived areas, although the relationship is not as strong as it is for the other two groups of drugs.We are aware that NHS boards are tackling the issue. It may be to do with factors that we have discussed previously, such as later presentation and later identification of conditions. The aim of programmes such as the keep well initiative, which involve health checks, is to focus attention on such areas.

Colin Beattie SNP Midlothian North and Musselburgh
link

I was interested in the comments that are made in paragraph 75 about the prescription of hypnotics and so on—I presume that they are uppers and downers, which are being given to people who are depressed and so forth. Does that indicate a higher level of depression?

Tricia Meldrum Audit Scotland
link

They are not antidepressants—they are drugs for anxiety. We did not look at antidepressants as part of our analysis. They are a separate class of drugs.

Colin Beattie SNP Midlothian North and Musselburgh
link

I am just trying to tease out some of the differences between the approach in deprived areas and the approach in better-off areas.

Tricia Meldrum Audit Scotland
link

Other research has shown a link between deprivation, depression and the prescribing of antidepressant medication.

James Dornan SNP Glasgow Cathcart
link

I have a question about paragraph 72, which says that although some practices in deprived areas have high levels of prescribing, other practices in the same areas sometimes have very low levels of prescribing. Can you explain that dichotomy? What can we do to ensure that everyone gets the same service?

Tricia Meldrum Audit Scotland
link

We presented that information with a view to asking whether practices, with the support of boards and prescribing advisers, could look at why that might be happening. The data could be used to identify where we might expect prescribing of particular drugs to be a bit higher or a bit lower, depending on the age and deprivation characteristics of the population that the practice serves. Where things are a wee bit out of kilter, the prescribing advisers and the GPs could look at why that might be and identify whether there is scope to increase prescribing or to decrease it.We were making the point that although there is a clear association between deprived areas and high levels of prescribing, there are still outliers at both ends of the scale where there is scope for more investigation locally to see what the issues might be and what could be done.

James Dornan SNP Glasgow Cathcart
link

On the face of it, does it look as if people in practices that have a higher level of prescribing are getting a better service, or is it possible that people in practices with a lower level of prescribing might be getting a better service, because the pharmacists are using the drugs more wisely?

Caroline Gardner Auditor General for Scotland
link

It is not possible to give a single answer to that question. It might be more useful to look at exhibit 15, which shows the different prescription rates for different individual drugs. As Tricia Meldrum said, for sleeping pills and anxiety drugs, the prescription rate is about four times higher in deprived areas than it is elsewhere, but the rate for statins is only about one and a half times higher. Given what we know about ill health in more deprived areas and the lifestyle factors such as obesity that can lead to a higher risk of heart disease, there is a question about whether we might expect that prescribing ratio to be higher in those deprived areas. The figures that we see are an average, because practices in an area will have a range of prescribing.That is why we think that it is important for GPs to sit down with their prescribing advisers and use the data to say, for example, “We look a bit low here. Should we be prescribing more of this particular class of drug?” or “We look very high on sleeping pills. Is there something we could do to reduce that?” It is about targeting what is happening in a particular practice and working over time to shift that to ensure that patients get the best care—whether that is more drugs, fewer drugs or different drugs.

Barbara Hurst Audit Scotland
link

We are definitely not querying individual GPs’ clinical decisions.

Barbara Hurst Audit Scotland
link

I just wanted to make it clear that that is down to their professional judgment. What is interesting is that NHS Greater Glasgow and Clyde is one of the boards that is doing really well in its management and support for GPs.

Colin Keir SNP Edinburgh Western
link

My question is about overstocking, which might have been better as a supplementary question.Over the past couple of years we have had a few incidents of severe weather conditions. Any industry must take such incidences into consideration when considering deliveries from suppliers to stockists. Have I missed anything in the report that considered that aspect? For example, with regard to the severe winter weather that we had over the Christmas and new year period a couple of years ago, is there evidence that has not been taken into consideration of

overstocking of drugs by care homes and pharmacies, which would have skewed the figures slightly?

Caroline Gardner Auditor General for Scotland
link

We have done that specific analysis. What we have seen and what we have heard from GPs, as well as what we have learned from research that has been done in England, is that there is a consistent pattern of people using good schemes that enable them to stock up before periods such as Christmas and new year, when practices are not open. We therefore see a peak in prescribing, but we do not see the reduction afterwards that we might expect as the pattern catches up across the year.

Caroline Gardner Auditor General for Scotland
link

There is a more general point to be made about the incentives all being for community pharmacists to prescribe because of the basis of payment, rather than to manage prescription in a more rounded way.

Colin Keir SNP Edinburgh Western
link

I asked my question because, for example, in some areas, roads were out of commission for the best part of a month, so I wonder whether such situations had been considered. My view differs from Ms Scanlon’s view, in that in such circumstances the ability to supply people who require a drug shows good practice rather than bad practice.

Caroline Gardner Auditor General for Scotland
link

I do not think that we have any evidence on the situation that you described.

Bob Doris SNP Glasgow
link

I turn to the variation in health boards’ performance on prescribing, as there were dramatic differences between the 14 health boards. The report picked up on differences in the prescribing support that is available. Are any mechanisms in place for boards to share best practice? Are there any imperatives to say that they must do that?

Tricia Meldrum Audit Scotland
link

Yes. There is a Scottish prescribing advisers network. I am not sure whether that is the right title, but there is an umbrella group of prescribing advisers who get together periodically, partly to share best practice, guidelines and work that they are doing. It is quite an active network. It is a small community, so they are quite switched on to what one another are doing.10:00

Tricia Meldrum Audit Scotland
link

I do not know—I am sorry.

Bob Doris SNP Glasgow
link

It is just that, with such dramatic differences remaining, I am keen to know how effective that group has been. It is such a good report, and we are looking for ways to continue to improve.I also sit on the Health and Sport Committee. We are finding significant variations in performance between the area drug and therapeutics committees—ADTCs—which put drugs on to formulary and consider these various matters at each health board. Do you believe that the mechanism that is in place for the sharing of best practice is appropriate? Your report suggests that improvement requires best practice to be achieved across all 14 boards, and that we still have to make significant savings. Are the structures that are currently in place working in relation to the sharing of best practice?

Barbara Hurst Audit Scotland
link

Yes, we think that this is an area where there is a lot of good communication across boards. The joy of it, in audit terms, is that it is so data rich. We are hopeful that, if we highlight some of the variations, boards will take those seriously and look at what they are doing differently from some of their counterparts. We hope that that, in combination with the systems that are in place, will help to drive the sharing of good practice.

Bob Doris SNP Glasgow
link

Should the boards be considering a target, such that, if you were to look again at this data and return with a follow-up piece of work in two years’ time, the poorest-performing boards would be 40 per cent closer to the best-performing boards? We cannot simply monitor the situation as a snapshot in time; we need to consider where we are in two or four years’ time.

Barbara Hurst Audit Scotland
link

Yes. As you say, this is a good-news story, so it is hard to think of there being poorly performing boards. However, it would be quite easy for us to take some of the indicators that we have tracked through from the very early days when we first looked at this and find out what happens in two years’ time. It will be up to boards to select the areas that they wish to prioritise, but there are some clear messages in the report for different boards about the areas where they might not be performing quite as well as other boards.

Caroline Gardner Auditor General for Scotland
link

I will present one example that we have been impressed by, which might help to colour that point for you. Exhibit 5 on page 11 of the report shows that NHS Forth Valley is bringing down its spending fast—that is shown by the orange line on the graph, which has come down a lot since 2010. NHS Forth Valley tells us that it is achieving that by learning from what NHS Greater Glasgow and Clyde, which has been one of the best-performing boards, has been doing and by looking at its examples of areas to target and ways to get prescribing advice working in practice. Boards are learning from one another, but there is no one thing that every board needs to do—it is about targeting those areas where boards have room for improvement and ensuring that they are paying attention to them.

Bob Doris SNP Glasgow
link

I am not seeking to rain on the parade of what is a good-news story, but it is our responsibility to go even further and to promote best practice in order to save even more money for the public purse and improve patient care. On the other committee on which I sit, we have been considering the roles of community pharmacists quite a lot. There are initiatives for improving prescribing methods, which individual health boards have invested in, but community pharmacists are in every community irrespective of specific initiatives. The ones I meet tell me that, if they had more time and more space in their pharmacy, they would sit down and have a chat with customers or service users who come into the pharmacy to discuss polypharmacy and other drug and medication options. In making your report, did you discover—separate from specific initiatives, but with regard to people popping into their community pharmacist on the high street, sometimes just for a lunch meal deal, for instance, in the case of one of the large commercial operators—that pharmacists need more time to work with patients?

Caroline Gardner Auditor General for Scotland
link

It is clear that there are some good initiatives in place already, and that there is scope for those to go further. We know that good pharmacists can make a big impact on patient care, and there are good examples of that. That takes us back to the point that we make in our report about using the community pharmacy contract to put incentives in place for that sort of development, rather than the incentive being payment per item prescribed. It is an area that is highly variable, because of the way in which the pharmacy service has developed over time. As you say, the different premises and different levels of staffing mean that what pharmacies can do is different in each part of Scotland. There is certainly room to go further, and we think that the contract is the mechanism for putting incentives in place for that to happen.

Bob Doris SNP Glasgow
link

Thank you for putting that on the public record.

Mark Griffin Lab Central Scotland
link

The figures that jump out from the report are the 11 per cent reduction in the cost of drugs against the backdrop of a 33 per cent increase in levels of prescribing. A big part of that has been attributed to more prescribing of generic drugs, but I want to drill a bit deeper into that. I ask my question without an in-depth knowledge of the patent and approval processes, so perhaps you will correct me if I go wrong. Has there been any evidence of changes in the approval process for drugs to be made available for prescribing? Obviously, if the time for which a drug is available for prescribing on patent is reduced, that reduces the cost to the NHS. Have any studies been done on the length of time for which drugs are available on patent for prescribing and whether there are differences in that between Scotland, the UK and Europe? That might explain the higher costs in Europe.

Caroline Gardner Auditor General for Scotland
link

I ask Tricia Meldrum to give us a short tutorial on the drug patent system.

Tricia Meldrum Audit Scotland
link

I am not aware that the length of time on patent is different in different parts of the UK—I would not think so, as the patents are at UK level. Sorry, but I do not know the minimum length of time for which a patent runs, but, at the start of the period that we looked at, one of the big drugs to come off patent was a commonly used statin. Our data show a huge increase in the amount of statin prescribing that switched to simvastatin when it came off patent and the price dropped dramatically.Another common statin is atorvastatin, which has just come off patent. It was a proprietary drug for seven years. There were moves to reduce prescribing of atorvastatin where it was clinically appropriate for another statin to be used, because atorvastatin was a higher-cost option. However, now that it has come off patent, the price is dropping dramatically, so it is becoming more cost effective. Obviously, the issue of patents has a big influence.The process for the introduction of new drugs is one stage back from our report, which looked at drugs that have been in place for a number of years. They have been through all the approval and licensing processes, and the issue is just the time for which they will be on patent. The issues to do with new drugs are different and do not have such a big impact on primary care prescribing. The new higher-cost drugs that are coming through are more specialist drugs that would be used in hospitals by specialists.

Iain Gray Lab The Convener · East Lothian
link

To follow up on that, nonetheless, in paragraphs 62 and 63 of the report, you refer to one aspect of the debate on new and expensive drugs, which is the end of the price regulation scheme at the end of this year and the proposed shift to value-based pricing. You state:“These changes make it more difficult to forecast potential changes in the spending and quantity of ... prescribing”.Might that issue undermine the progress that has been made and reported on in the report?

Tricia Meldrum Audit Scotland
link

We just do not know what that will do to prices. We were simply flagging up an area of uncertainty for the future.

Iain Gray Lab The Convener · East Lothian
link

Mr Doris can ask a question on that if it is very brief.

Bob Doris SNP Glasgow
link

I promise that it will be, because the Health and Sport Committee is considering value-based pricing as well. Will Audit Scotland have to make significant changes to its methods of auditing, given that it will be considering the social on-costs of not prescribing in terms of social care and residential accommodation? Has Audit Scotland been able to consider that yet, or does it need more information from the UK Government before it can start to address that?

Caroline Gardner Auditor General for Scotland
link

As Barbara Hurst said, GP prescribing is a data-rich area. As far as we understand, that data, which gives us the core of what is going on for cost and volume of drugs prescribed, will continue to be available. However, next time, we may well want to consider the wider impact, particularly in care homes, for example.We mention in the report the challenges of polypharmacy. Ms Scanlon mentioned the risks of care homes overstocking drugs because of the conditions that they are trying to manage. We want to open up future work in the area and consider some of the social impacts of prescribing or not prescribing and where the right balance might sit.

Iain Gray Lab The Convener · East Lothian
link

Mr Coffey, you are always keen to find the positives. It should not be too hard in this case.

Willie Coffey SNP Kilmarnock and Irvine Valley
link

Thank you very much, convener. I simply echo your opening remarks and say that it is a remarkable and positive report. However, we always look to see where improvements can be made, and the Auditor General has rightly pointed to a few examples where that possibility exists.I am pleased to see that the policy of abolishing prescription charges has not resulted in any noticeable increase in the quantity of prescriptions being taken up—I think that that is in the key messages report that the Auditor General gave us. That fact could tell us a number of things. It could tell us that, prior to and after the policy’s implementation, people—particularly in our most deprived communities or communities most in need—by and large took up prescriptions and medicines. However, the impact of the policy on cost is significant and should benefit people in those communities.My attention was drawn to exhibit 6. It tells an interesting story in relation to NHS Greater Glasgow and Clyde. That graphic shows that the health board is the best on the quantity of drugs prescribed per weighted head of population and on cost. That is very welcome, but how can there be such a good story for Glasgow given the high numbers of Scottish index of multiple deprivation zones in the city? We hear all the time that Glasgow has the highest proportion of deprived populations, but the performance from NHS Greater Glasgow and Clyde seems to be very positive. I ask the Auditor General to explain that.

Caroline Gardner Auditor General for Scotland
link

I will ask Tricia Meldrum to give you some of the details, but you are absolutely right that NHS Greater Glasgow and Clyde is doing a really good job. Some other boards, such as Forth Valley NHS Board, are learning from its experience.As a starting point, if you look at exhibit 8, you will see that NHS Greater Glasgow and Clyde is right at the top end for prescribing support that is available to GPs. It is fourth in numerical terms but, given the scale of the board, a significant amount of prescribing support is available to its general practice teams. We see the impact of that.I ask Tricia Meldrum to pick that up and give us a bit more detail about what we know about how NHS Greater Glasgow and Clyde is doing that.

Tricia Meldrum Audit Scotland
link

NHS Greater Glasgow and Clyde has a multidisciplinary team, which includes analysts, and makes good use of the available data. There are also some economies of scale. Because NHS Greater Glasgow and Clyde is a bigger board and has higher staff numbers, the team is able to specialise in different ways from some of the other support teams. It also works with dieticians and other people who have specialist knowledge of particular aspects of drugs.The team members are also based in practices and work directly with GPs part of the time. The team has a history and has been in place over a number of years. The board has introduced a number of spend-to-save initiatives. It has set quite clear targets and decided to introduce certain posts but stipulated that they should pay for themselves and make additional savings that it can then reinvest in further improvements and further savings.The board has well-targeted initiatives in place. They are being shared through the national networks and some of that good practice is being rolled out in other places.The data are based on weighted population, so they take account of aspects such as the deprivation profile of the population.10:15

Willie Coffey SNP Kilmarnock and Irvine Valley
link

That message is strong and it chimes with what Harry Burns told us at a previous meeting—he said that we should grab good practice, make it consistent across Scotland and share it as well and as quickly as we can. That is important.One opportunity to reduce waste that has been mentioned is from saving by prescribing generic rather than branded drugs. The performance on prescribing generic drugs is pretty good. The answer to a question that I asked recently showed that 83 per cent of drugs are generic, and I understand that that figure has improved by 10 per cent in the past 10 years. The Auditor General said that making further improvements in such prescribing would provide the opportunity to save about £2 million, which would be welcome but would not be a huge gain in comparison with the overall cake.You have made recommendations about where we can make savings. How do we reduce the waste of drugs? I understand that there are quite a number of clinical reasons why drugs are wasted—for example, when people go into hospital, they do not take their medicines with them; they are given new medicines. The situation is similar when people leave hospital. How can our health boards make further improvements when there might be clinical reasons for the waste that is in the system?

Caroline Gardner Auditor General for Scotland
link

You are right that the performance on prescribing generic drugs has been really good in the past 10 years. There was a lot of branded drug prescription that was hard to justify in cost or quality terms; now, we estimate that the potential further saving would be very small.We say that further savings of about £26 million are available, most of which would come from reducing waste that relates to repeat prescriptions or drugs that are prescribed but no longer taken and from the category of drugs that Tricia Meldrum talked about—drugs that are classified as less suitable for prescribing. There is no one way of making savings. Most health boards have done some of the things that will make an improvement, but there is scope to do more and learn from one another, in line with the question that Mr Doris asked.We must reflect the fact that the picture is changing. Every year, more drugs come off patent and more opportunities are available to shift from a branded drug to a generic equivalent. New drugs become available, which makes some existing ones less suitable to prescribe. People need to use the existing infrastructure—such as prescribing advisers and formularies—and keep on using the data day by day.The spend on prescriptions is big—it involves £1 billion and 91 million prescriptions a year. Keeping attention on that as the situation changes is the way to get the savings and to ensure that patients get the drugs that they need to stay as healthy as they can be.

Tricia Meldrum Audit Scotland
link

A more recent development in the information that is available is that almost all prescriptions now have a patient’s community health index number—their unique identifying number—which means that it is becoming possible to do much more analysis at the patient level. We can see how many people have a number of drugs prescribed for them and how often their prescriptions are repeated.That means that boards and GPs can work together to target areas for medication reviews and can look at people who are taking lots of different drugs. That data set has been linked to prescribing data only recently; it provides much more powerful information for looking at some of the issues.

Iain Gray Lab The Convener · East Lothian
link

Ms Scanlon has a very short final question.

Mary Scanlon Con Highlands and Islands
link

I ask for advice on saving money, which Willie Coffey asked about. It is not surprising that, as exhibit 11 shows, the average spend on drugs by age group rises as people get older. I have just remembered that the Mental Welfare Commission for Scotland told the Health and Sport Committee that more than 70 per cent of people in care homes were on antipsychotic drugs, many of which were unnecessary. Many people in care homes do not see their GPs, and pharmacists do not go into care homes. Is there a missing link? Should we look at a way of saving money in relation to that group, and how could that be done?

Tricia Meldrum Audit Scotland
link

That very much relates to medication reviews and looking at whether variation is appropriate, which involves clinical judgments. It is not for us to comment on clinical judgments; it is for prescribers—with support from others—to see whether prescriptions are always appropriate. The Royal Pharmaceutical Society recently issued guidance on the care of people in care homes, where it feels that scope for improvement exists.

Iain Gray Lab The Convener · East Lothian
link

I thank our witnesses. Later, we will consider our approach to the report.The next item is on a different, though related, topic. I suspend the meeting to allow a change of witnesses and for a comfort break.10:20 Meeting suspended.

10:27 On resuming—

  1. 09:30 Decision on Taking Business in Private Procedure · 1
  2. 09:30 Section 23 Reports Committee business · 75
  3. 09:30 Section 23 Reports Committee business · 138
  4. 09:30 Section 23 Reports Committee business · 19

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.